Ameriprise Financial Inc. Grows Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Ameriprise Financial Inc. increased its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 14.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 715,672 shares of the biotechnology company’s stock after buying an additional 88,542 shares during the period. Ameriprise Financial Inc.’s holdings in ADMA Biologics were worth $12,274,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ADMA. Perpetual Ltd acquired a new position in ADMA Biologics in the 4th quarter valued at about $62,300,000. Allspring Global Investments Holdings LLC raised its stake in ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. B Group Inc. acquired a new position in ADMA Biologics in the 4th quarter valued at about $39,231,000. Raymond James Financial Inc. acquired a new position in ADMA Biologics in the 4th quarter valued at about $19,076,000. Finally, Arrowstreet Capital Limited Partnership raised its stake in ADMA Biologics by 57.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company’s stock valued at $47,380,000 after purchasing an additional 1,013,456 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ADMA. Raymond James increased their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a report on Thursday, May 8th. StockNews.com lowered shares of ADMA Biologics from a “hold” rating to a “sell” rating in a report on Friday, May 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ADMA Biologics has a consensus rating of “Moderate Buy” and a consensus price target of $24.25.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.69 on Monday. ADMA Biologics, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $25.67. The firm’s 50-day simple moving average is $20.49 and its 200 day simple moving average is $18.86. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.70 billion, a P/E ratio of 70.32 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to analyst estimates of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. ADMA Biologics’s revenue was up 40.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.08 earnings per share. Equities analysts expect that ADMA Biologics, Inc. will post 0.51 EPS for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.